UK markets close in 7 hours 57 minutes

Oncolytics Biotech Inc. (ONCY)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0300+0.0200 (+1.98%)
At close: 04:00PM EDT
1.0295 -0.00 (-0.05%)
After hours: 06:25PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0100
Open1.0300
Bid1.0000 x 500
Ask1.0300 x 100
Day's range1.0099 - 1.0300
52-week range0.8800 - 3.3900
Volume123,786
Avg. volume401,760
Market cap77.682M
Beta (5Y monthly)1.49
PE ratio (TTM)N/A
EPS (TTM)-0.3000
Earnings date03 May 2024 - 07 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.83
  • Insider Monkey

    Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript

    Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript March 9, 2024 Oncolytics Biotech Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Oncolytics Biotech’s Fourth Quarter and Full Year 2023 Conference Call. All participants […]

  • PR Newswire

    Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

    Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023. All dollar amounts are expressed in Canadian currency unless otherwise noted.

  • PR Newswire

    Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

    Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI; Germany's regulatory